Serum miRNA expression profile as a prognostic biomarker of stage II/III colorectal adenocarcinoma

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Li, Jialu ^a,b   Liu, Yang ^c   Wang, Cheng ^b   Deng, Ting ^a   Liang, Hongwei ^b   Wang, Yifei ^d   Huang, Dingzhi ^a   Fan, Qian ^a,b   Wang, Xia ^a   Ning, Tao ^a   Liu, Rui ^a   Zhang, Chen Yu ^b   Zen, Ke ^b   Chen, Xi ^b   Ba, Yi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

^c THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^d HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; TRANSCRIPTOME; TUMOR MARKER;

ADENOCARCINOMA; AGED; BLOOD; CANCER STAGING; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; PROCEDURES; PROGNOSIS; RISK FACTOR; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; TRANSCRIPTOME;

EID: 84938877229     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12921     Document Type: Article

References (41)

1. Jemal, A. et al. Global cancer statistics. CA: A Cancer Journal for Clinicians 61, 69-90 (2011).
2. André, T. et al. Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial. Journal of Clinical Oncology 27, 3109-3116 (2009).
3. O'Connell, M. J. et al. Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set. Journal of Clinical Oncology 26, 2336-2341 (2008).
4. Andre, T. et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27, 3109-3116 (2009).
5. Twelves, C. et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352, 2696-2704 (2005).
6. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345, 939-944 (1995).
7. O'Connell, M. J. et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15, 246-250 (1997).
8. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
9. Calin, G. A. et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences of the United States of America 101, 2999-3004 (2004).
10. Chen, X. et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18, 997-1006 (2008).
11. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105, 10513-10518 (2008).
12. Ng, E. K. et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58, 1375-1381 (2009).
13. Toiyama, Y. et al. Serum miR-21 as a Diagnostic and Prognostic Biomarker in Colorectal Cancer. J Natl Cancer Inst 105, 849-859 (2013).
14. Luo, X., Burwinkel, B., Tao, S. & Brenner, H. MicroRNA Signatures: Novel Biomarker for Colorectal Cancer? Cancer Epidemiology Biomarkers & Prevention 20, 1272-1286 (2011).
15. Yong, F. L., Law, C. W. & Wang, C. W. Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer 13, 280 (2013).
16. Luo, X., Stock, C., Burwinkel, B. & Brenner, H. Identification and evaluation of plasma MicroRNAs for early detection of colorectal cancer. PLoS One 8, e62880 (2013).
17. Huang, Z. et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 127, 118-126 (2010).
18. Yong, F. L., Law, C. W. & Wang, C. W. Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer 13, 280 (2013).
19. Toiyama, Y. et al. Serum miR-21 as a Diagnostic and Prognostic Biomarker in Colorectal Cancer. Journal of the National Cancer Institute 105, 849-859 (2013).
20. Pu, X. X. et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 25, 1674-1680 (2010).
21. Cheng, H. et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 6, e17745 (2011).
22. Chang, K. H., Mestdagh, P., Vandesompele, J., Kerin, M. J. & Miller, N. MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer 10, 173 (2010).
23. Kroh, E. M., Parkin, R. K., Mitchell, P. S. & Tewari, M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50, 298-301 (2010).
24. Chen, X. et al. A combination of Let-7d, Let-7g and Let-7i serves as a stable reference for normalization of serum microRNAs. PLoS One 8, e79652 (2013).
25. Michael, M. Z., SM, O.C., van Holst Pellekaan, N.G., Young, G.P. & James, R.J. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1, 882-891 (2003).
26. Bandres, E. et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 5, 29 (2006).
27. Cummins, J. M. et al. The colorectal microRNAome. Proc Natl Acad Sci USA 103, 3687-3692 (2006).
28. Xu, Q. et al. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res 40, 761-774 (2012).
29. Gregersen, L. H. et al. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One 5, e8836 (2010).
30. Zhang, J. et al. Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer 117, 86-95 (2011).
31. Bauer, K. M. & Hummon, A. B. Effects of the miR-143/-145 microRNA cluster on the colon cancer proteome and transcriptome. J Proteome Res 11, 4744-4754 (2012).
32. Schetter, A. J. et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. Jama 299, 425-436 (2008).
33. Díaz, R. et al. Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes, Chromosomes and Cancer 47, 794-802 (2008).
34. Ma, Y. et al. Candidate microRNA biomarkers in human colorectal cancer: Systematic review profiling studies and experimental validation. International Journal of Cancer 130, 2077-2087 (2012).
35. Hayashita, Y. et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 65, 9628-9632 (2005).
36. Takakura, S. et al. Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci 99, 1147-1154 (2008).
37. Humphreys, K. J., Cobiac, L., Le Leu, R. K., Van der Hoek, M. B. & Michael, M. Z. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol Carcinog 52, 459-474 (2013).
38. Gaedcke, J. et al. The rectal cancer microRNAome - microRNA expression in rectal cancer and matched normal mucosa. Clin Cancer Res 18, 4919-4930 (2012).
39. Edge, S. B. & American Joint Committee on Cancer. AJCC cancer staging manual (Springer, New York, 2010).
40. Liu, R. et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 47, 784-791 (2011).
41. Wu, C. et al. Diagnostic and prognostic implications of a serum miRNA panel in oesophageal squamous cell carcinoma. PLoS One 9, e92292 (2014).